Scan to Download ios&Android APP

Trade Agios Pharmaceuticals, Inc. - AGIO CFD

28.33
9.75%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 25.94
Open* 26.67
Day's Range* 26.57 - 26.57
1-Year Change* -38.87%
Volume N/A
Average Vol. (3m) 15.0863
52 wk Range N/A
Market Cap 1546.96
P/E Ratio N/A
Shares Outstanding 54818000
Revenue 6.414
EPS -6.70569
Dividend (Yield %) N/A
Beta 1.2398
Next Earnings Date Nov 1, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Aug 11, 2022 25.94 -2.28 -8.08% 28.22 28.23 25.72
Aug 10, 2022 28.15 1.19 4.41% 26.96 28.31 26.92
Aug 9, 2022 27.32 -1.02 -3.60% 28.34 28.89 27.03
Aug 8, 2022 29.31 0.79 2.77% 28.52 29.45 28.09
Aug 5, 2022 29.67 2.18 7.93% 27.49 29.97 27.02
Aug 4, 2022 28.56 3.31 13.11% 25.25 28.57 24.98
Aug 3, 2022 24.85 2.00 8.75% 22.85 24.91 22.85
Aug 2, 2022 22.88 2.02 9.68% 20.86 23.23 20.86
Aug 1, 2022 21.23 0.28 1.34% 20.95 21.74 20.87
Jul 29, 2022 21.51 0.54 2.58% 20.97 21.56 20.71
Jul 28, 2022 21.49 0.12 0.56% 21.37 21.79 20.80
Jul 27, 2022 21.55 1.00 4.87% 20.55 21.66 20.36
Jul 26, 2022 19.45 -0.02 -0.10% 19.47 20.28 19.37
Jul 25, 2022 19.94 -0.52 -2.54% 20.46 20.47 19.74
Jul 22, 2022 20.46 -1.24 -5.71% 21.70 21.94 20.32
Jul 21, 2022 21.76 0.00 0.00% 21.76 21.88 21.44
Jul 20, 2022 21.81 0.18 0.83% 21.63 22.40 21.47
Jul 19, 2022 21.56 0.42 1.99% 21.14 21.83 21.00
Jul 18, 2022 20.94 -1.39 -6.22% 22.33 22.89 20.83
Jul 15, 2022 22.25 -0.81 -3.51% 23.06 23.06 21.67

Agios Pharmaceuticals, Inc. Events

Time (UTC) Country Event
Tuesday, November 1, 2022
12:30
  US
Q3 2022 Agios Pharmaceuticals Inc Earnings Release
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 69.892 43.011 94.387 0 0 0
Revenue 69.892 43.011 94.387
Total Operating Expense 270.877 363.805 456.866 316.269 335.916 371.779
Selling/General/Admin. Expenses, Total 50.714 71.124 114.145 102.007 115.105 121.445
Research & Development 220.163 292.681 341.324 214.262 220.811 256.973
Operating Income -200.985 -320.794 -362.479 -316.269 -335.916 -371.779
Interest Income (Expense), Net Non-Operating 2.514 6.124 16.451 14.861 6.611 0.836
Net Income Before Taxes -198.471 -314.67 -346.028 -301.408 -329.305 -356.51
Net Income After Taxes -198.471 -314.67 -346.028 -301.408 -329.305 -356.51
Net Income Before Extra. Items -198.471 -314.67 -346.028 -301.408 -329.305 -356.51
Net Income -198.471 -314.67 -346.028 -411.472 -327.37 1604.71
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -198.471 -314.67 -346.028 -301.408 -329.305 -356.51
Income Available to Common Incl. Extra. Items -198.471 -314.67 -346.028 -411.472 -327.37 1604.71
Diluted Net Income -198.471 -314.67 -346.028 -411.472 -327.37 1604.71
Diluted Weighted Average Shares 39.1264 46.5876 57.4183 59.9945 68.9979 60.4473
Diluted EPS Excluding Extraordinary Items -5.07256 -6.75437 -6.02644 -5.02392 -4.77268 -5.89786
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS -5.07256 -6.75437 -6.02644 -5.02392 -4.77268 -6.00769
Total Extraordinary Items 0 -110.064 1.935 1961.22
Cost of Revenue, Total 1.397
Gross Profit 92.99
Unusual Expense (Income) 0 0 -6.639
Other, Net 0 0 14.433
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 0 0 0 0.832
Total Operating Expense 91.217 89.222 89.156 102.184 99.273
Selling/General/Admin. Expenses, Total 33.55 29.215 27.152 31.528 31.515
Research & Development 57.667 62.007 64 73.299 70.123
Operating Income -91.217 -89.222 -89.156 -102.184 -98.441
Interest Income (Expense), Net Non-Operating 0.34 -0.092 0.256 0.332 0.694
Net Income Before Taxes -90.877 -82.79 -84.259 -98.584 -94.774
Net Income After Taxes -90.877 -82.79 -84.259 -98.584 -94.774
Net Income Before Extra. Items -90.877 -82.79 -84.259 -98.584 -94.774
Total Extraordinary Items 1965.2 -3.427 -4.507 3.957 0
Net Income 1874.32 -86.217 -88.766 -94.627 -94.774
Income Available to Common Excl. Extra. Items -90.877 -82.79 -84.259 -98.584 -94.774
Income Available to Common Incl. Extra. Items 1874.32 -86.217 -88.766 -94.627 -94.774
Diluted Net Income 1874.32 -86.217 -88.766 -94.627 -94.774
Diluted Weighted Average Shares 69.5435 61.067 57.0482 54.2801 54.5555
Diluted EPS Excluding Extraordinary Items -1.30676 -1.35572 -1.47698 -1.81621 -1.7372
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.30676 -1.38848 -1.51197 -1.8649 -1.78677
Unusual Expense (Income) -2 -1.996 -2.643 -2.704
Other, Net 6.524 4.641 3.268 2.973
Revenue 0.832
Cost of Revenue, Total 0.339
Gross Profit 0.493
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 559.892 445.261 613.78 611.704 636.677 1064.23
Cash and Short Term Investments 541.314 423.936 585.302 564.877 572.929 1020.02
Cash & Equivalents 160.754 102.724 70.502 80.931 127.436 203.126
Short Term Investments 380.56 321.212 514.8 483.946 445.493 816.892
Total Receivables, Net 8.314 3.839 10.442 15.319 25.399 4.378
Prepaid Expenses 10.264 17.486 17.167 24.177 23.651 39.835
Total Assets 619.094 614.397 858.457 890.741 852.952 1437.74
Property/Plant/Equipment, Total - Net 25.337 24.431 24.32 126.108 117.542 104.23
Property/Plant/Equipment, Total - Gross 38.709 43.828 50.472 158.22 158.895 149.204
Accumulated Depreciation, Total -13.372 -19.397 -26.152 -32.112 -41.353 -44.974
Long Term Investments 32.25 143.814 220.119 152.929 97.608 266.375
Other Long Term Assets, Total 1.615 0.891 0.238 0 1.125 2.9
Total Current Liabilities 88.433 94.941 93.503 92.886 94.394 59.826
Accounts Payable 17.106 22.767 17.88 21.896 26.844 16.7
Accrued Expenses 32.002 34.031 42.147 59.784 67.233 42.795
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 39.325 38.143 33.476 10.933 0 0
Total Liabilities 260.503 238.894 170.92 250.213 453.452 145.761
Total Long Term Debt 0 0 0 0.673 0.331 0.276
Other Liabilities, Total 172.07 143.953 77.417 156.654 358.727 85.659
Total Equity 358.591 375.503 687.537 640.528 399.5 1291.97
Common Stock 0.042 0.049 0.058 0.068 0.069 0.071
Additional Paid-In Capital 842.013 1174.9 1794.28 2156.36 2242.8 2334.35
Retained Earnings (Accumulated Deficit) -483.151 -798.061 -1104.63 -1516.1 -1843.47 -238.76
Other Equity, Total -0.313 -1.389 -2.171 0.202 0.105 -1.198
Total Liabilities & Shareholders’ Equity 619.094 614.397 858.457 890.741 852.952 1437.74
Total Common Shares Outstanding 42.2204 48.8261 58.2187 68.4011 69.2939 54.3342
Accounts Receivable - Trade, Net 1.222 7.31 11.852 21.328
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Total Inventory 0.869 7.331 14.698
Current Port. of LT Debt/Capital Leases 0.273 0.317 0.331
Capital Lease Obligations 0.673 0.331 0.276
Total Preferred Shares Outstanding 0 0 0
Other Current Assets, Total 0
Treasury Stock - Common -802.486
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 2355.11 1702.56 1305.29 1064.23 975.145
Cash and Short Term Investments 2335.6 1672.99 1266.06 1020.02 923.529
Cash & Equivalents 1888.03 969.124 400.224 203.126 80.026
Short Term Investments 447.578 703.864 865.833 816.892 843.503
Prepaid Expenses 19.511 21.443 32.238 39.835 43.226
Other Current Assets, Total 0 0 0 0
Total Assets 2488.43 1874.6 1541.5 1437.74 1335.86
Property/Plant/Equipment, Total - Net 111.722 107.828 103.174 104.23 101.978
Long Term Investments 21.598 61.313 130.139 266.375 255.836
Other Long Term Assets, Total 0 2.9 2.9 2.9 2.9
Total Current Liabilities 96.504 60.649 57.896 59.826 45.792
Accounts Payable 51.224 7.654 10.308 16.7 11.551
Accrued Expenses 31.589 44.986 39.117 42.795 31.491
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.321 0.839 0.412 0.331 0.25
Other Current Liabilities, Total 13.37 7.17 8.059 0 2.5
Total Liabilities 191.804 152.787 146.736 145.761 128.406
Total Long Term Debt 0.248 0.167 0 0.276 0.276
Capital Lease Obligations 0.248 0.167 0 0.276 0.276
Other Liabilities, Total 95.052 91.971 88.84 85.659 82.338
Total Equity 2296.63 1721.82 1394.76 1291.97 1207.45
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.07 0.07 0.071 0.071 0.071
Additional Paid-In Capital 2265.71 2306.3 2322.46 2334.35 2351.15
Retained Earnings (Accumulated Deficit) 30.85 -55.367 -144.133 -238.76 -333.534
Other Equity, Total -0.003 -0.144 -0.198 -1.198 -7.745
Total Liabilities & Shareholders’ Equity 2488.43 1874.6 1541.5 1437.74 1335.86
Total Common Shares Outstanding 69.8122 59.9108 54.7152 54.3342 54.7769
Total Preferred Shares Outstanding 0 0 0 0 0
Total Receivables, Net 8.131 6.99 4.378 5.905
Treasury Stock - Common -529.047 -783.438 -802.486 -802.486
Accounts Receivable - Trade, Net 0.54
Total Inventory 2.485
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -198.471 -314.67 -346.028 -411.472 -327.37 1604.71
Cash From Operating Activities 38.562 -285.232 -304.421 -370.622 -290.759 -407.32
Cash From Operating Activities 5.708 6.432 7.172 8.087 9.984 9.24
Non-Cash Items 42.859 47.838 69.54 78.762 97.664 -1984.45
Cash Taxes Paid 0
Changes in Working Capital 188.466 -24.832 -35.105 -45.999 -71.037 -36.822
Cash From Investing Activities -119.35 -57.908 -273.825 91.44 75.746 1248.78
Capital Expenditures -9.915 -4.627 -6.986 -12.171 -14.909 -5.741
Other Investing Cash Flow Items, Total -109.435 -53.281 -266.839 103.611 90.655 1254.52
Cash From Financing Activities 169.778 285.11 546.024 289.611 261.518 -765.768
Financing Cash Flow Items -0.23 0.638 -0.391 0 250.537 0
Issuance (Retirement) of Stock, Net 170.008 284.472 546.415 289.724 11.317 -765.19
Net Change in Cash 88.99 -58.03 -32.222 10.429 46.505 75.69
Issuance (Retirement) of Debt, Net -0.113 -0.336 -0.578
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line 1874.32 1788.11 1699.34 1604.71 -94.774
Cash From Operating Activities -120.749 -238.043 -323.227 -407.32 -97.735
Cash From Operating Activities 2.479 4.829 7.038 9.24 2.478
Non-Cash Items -1976.79 -2002.66 -1992.05 -1984.45 19.096
Changes in Working Capital -20.763 -28.324 -37.558 -36.822 -24.535
Cash From Investing Activities 1874.08 1575.93 1343.2 1248.78 -26.573
Capital Expenditures -1.012 -1.261 -1.239 -5.741 -2.804
Other Investing Cash Flow Items, Total 1875.09 1577.19 1344.44 1254.52 -23.769
Cash From Financing Activities 7.261 -496.197 -747.182 -765.768 1.208
Issuance (Retirement) of Stock, Net 7.347 -496.027 -746.409 -765.19 1.289
Issuance (Retirement) of Debt, Net -0.086 -0.17 -0.773 -0.578 -0.081
Net Change in Cash 1760.59 841.688 272.788 75.69 -123.1
Financing Cash Flow Items 0 0 0 0

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Agios Pharmaceuticals, Inc. Company profile

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Agios Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items increased 8% to $356.5M. Higher net loss reflects Research and development increase of 20% to $232.4M (expense), General and administrative increase of 15% to $92.5M (expense), Interest Income decrease of 87% to $836K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.77 to -$5.90.

Equity composition

Common Stock $.001 Par, Shares auth and O/s after the offering: 78.3 M auth., 29,380,399 issd. Insider Owns approx.38.04%.(After the IPO) IPO:TBA.

Industry: Bio Therapeutic Drugs

88 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US

Income statement

People Also Watch

US Crude Oil Spot

91.73 Price
-1.740% 1D Chg, %
Long position overnight fee 0.0138%
Short position overnight fee -0.0310%
Overnight fee time 21:00 (UTC)
Spread 0.03

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading